Protein Biomarkers for Detecting Cancer

html xmlns=”http://www.w3.org/1999/xhtml”>


22

Protein Biomarkers for Detecting Cancer


Molecular Screening


Susan Fisher and H. Ewa Witkowska


No matter how many mistakes you make or how slow you progress, you are still way ahead of everyone who isn’t trying.


(http://www.marcandangel.com/2012/06/08/60-quotes-change-the-way-you-think/)



Biomarkers of early cancer detection, specific markers of a malignancy type, and predictive markers of response to treatment will aid in the early diagnosis and selection of the most efficient therapies. An exponential growth in technologies has been achieved toward this goal in the past decade. However, it is safe to say that the field of disease biomarkers produced many more publications on the subject than actual “clinically actionable” targets. By no means a criticism, this statement reflects on the status quo of a discipline that has been “trying really hard” but finding the goal more elusive with each step forward. 1 Why has the progress been slow? Is it just the technology that is not on par with the complexity of human biology? Or perhaps, by focusing mainly on a paradigm of “DNA-mRNA-protein” as a fundamental driving force that defines a phenotype, are we oversimplifying and hence misinterpreting a system? 2,3 We bring these very general questions to the attention of the reader for two reasons: first to spark a debate on the fundamental issues that biomarker discovery entails and second to put our detailed proteomics discussion into the perspective within the larger context of biomarker discovery.

Establishing a panel of biomarkers for early diagnosis of cancer holds tremendous promise but also faces daunting obstacles. The major challenge stems from the very nature of a biological system, its complexity, dynamics, variability, and versatility all making it difficult to draw clear lines between a state that would be considered normal and one that appears to be slightly different and in danger of becoming abnormal. Then come barriers of logistics, such as a dichotomy between a need to mainly rely on population studies while facing tremendous intra- and interpersonal phenotypic variability, defining adequate controls, availability of specimens, and the danger of their potential adulteration before analysis (i.e., in the course of collection, processing, and storage). Last but not least is the requirement for sensitive technologies capable of measuring target compounds directly from a biological milieu with a level of specificity and selectivity that allows differentiation among discrete cohorts of individuals/patients that is reliable enough to justify the risk of acting on specific clinical modalities. There is a growing recognition that achieving true breakthroughs in the use of biomarkers to improve human conditions, while delivering health care in an economically sustainable way, requires concerted and coordinated efforts of stakeholders across disciplines and across borders. A large consortium of authors has recently published an in-depth analysis of the status of implementation of proteomics biomarkers of disease with a focus on postdiscovery/postvalidation barriers and outlined a need for a roadmap to biomarker implementation. 4 In our review, we concentrate on the preimplementation stages of the biomarker pipeline from the perspective of technologies that are currently available for biomarker discovery and validation, with a focus on protein biomarkers for which mass spectrometry (MS) plays a primary role.

The discipline of MS-based proteomics 5 emerged through a serendipitous convergence of major technological developments in DNA sequencing, MS analysis of proteins/peptides and bioinformatics. In the enthusiasm that followed the success of the Human Genome Project, it appeared that understanding how the functional phenotype of a cell/tissue/organism relates to its protein/peptide repertoire was imminent, leading to exaggerated expectations that the new technology of proteomics would deliver meaningful results in a short time. A rush for quick success resulted in controversies and disappointments, and unavoidably triggered questions as to the fundamental validity and practical usefulness of proteomics approaches. 68 The involvement of funding agencies (e.g., the National Cancer Institute [NCI]), which funded programs aimed at addressing various stumbling blocks of proteomics technologies (e.g., the Clinical Proteomics Technologies for Cancer), 915 and of professional organizations and consortia (e.g., the Human Proteome Organization [HUPO] 1620 and the Proteomics Specification in Time and Space [PROSPECTS] Network 21 ) has been crucial, providing funding and building foundations and collaborations among various disciplines to ensure future success in developing protein-based biomarkers of disease. Now, after more than a decade of intense effort, the promise of proteomics remains valid. Accumulated experience, however, required reassessment of the prospects of achieving quick payoffs—especially in the context of translational research, as illustrated by a recent breast cancer biomarker study using an animal model that is reviewed at the end of this chapter. Nevertheless, the field is progressing steadily, and the lessons learned in the early days of the proteomics bonanza are informing the directions of new developments. 2230 Thousands of papers on the subject have been published to date. Here we focus on selected aspects of method development that, in our opinion, will play a significant role in moving this effort toward its eventual success.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Feb 15, 2017 | Posted by in ONCOLOGY | Comments Off on Protein Biomarkers for Detecting Cancer

Full access? Get Clinical Tree

Get Clinical Tree app for offline access